Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech

Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 billion biobucks pact with oral macrocycle drug start-up Orbis Medicines.